{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457123854
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[Interleukin 6|IL-6]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 468715-71-1
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Elsilimomab''' (also known as '''B-E8''') is a [[mouse]] [[monoclonal antibody]]<ref>{{cite web |url=http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf |title=WHO Drug Information |quote=p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer }}</ref> and an [[immunosuppressive drug]].{{Citation needed|date=September 2009}}

It (OPR-003) targets (and blocks) [[Interleukin-6]].<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/first-fully-human-anti-il6-antibody-under-development/6779735/ |title=First Fully Human Anti-IL6 Antibody Under Development |date=Oct 2006 }}</ref>

It has undergone a number of early stage clinical trails, e.g. for [[lymphoma]] and [[myeloma]].<ref name=F2009>{{cite journal |title=A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma |author=Fulciniti et al. |year=2009 |pmc=2787636 |pmid=19934301 |last2=Hideshima |first2=T |last3=Vermot-Desroches |first3=C |last4=Pozzi |first4=S |last5=Nanjappa |first5=P |last6=Shen |first6=Z |last7=Patel |first7=N |last8=Smith |first8=ES |last9=Wang |first9=W |last10=Prabhala |first10=R. |last11=Tai |first11=Y.-t. |last12=Tassone |first12=P. |last13=Anderson |first13=K. C. |last14=Munshi |first14=N. C. |volume=15 |issue=23 |pages=7144â€“52 |doi=10.1158/1078-0432.CCR-09-1483 |journal=Clinical Cancer Research|display-authors=8 }}</ref>

It was used as a template to develop a high-affinity, antagonist, fully human [[anti-IL-6]] [[mAb 1339]].<ref name=F2009/>

==References==
{{Reflist}}

{{Immunosuppressants}}
{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}